Aurinia Pharmaceuticals (AUPH) Work In Process (2023 - 2026)

Aurinia Pharmaceuticals' Work In Process history runs 4 years deep, the most recent figure standing at $41.4 million for Q1 2026.

• Quarterly Work In Process fell 0.79% year-over-year to $41.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.4 million (down 0.79% YoY) and the FY2025 annual result came in at $44.7 million, up 21.93% from the prior year.
• Work In Process was $41.4 million for Q1 2026 at Aurinia Pharmaceuticals, down from $44.7 million in the prior quarter.
• Across five years, Work In Process topped out at $44.7 million in Q4 2025 and bottomed at $36.6 million in Q4 2024.
• A 4-year average of $41.1 million and a median of $41.7 million in 2025 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2024 — Work In Process retreated 2.01% — and 2025, when it climbed 21.93%.
• Aurinia Pharmaceuticals' Work In Process stood at $37.4 million in 2023, then slipped by 2.01% to $36.6 million in 2024, then gained by 21.93% to $44.7 million in 2025, then slipped by 7.24% to $41.4 million in 2026.
• Business Quant data shows AUPH's Work In Process at $41.4 million in Q1 2026, $44.7 million in Q4 2025, and $42.6 million in Q3 2025.